These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36746274)

  • 21. Outbreaks of imipenem resistant Acinetobacter baumannii producing OXA-23 beta-lactamase in a tertiary care hospital in Korea.
    Yang HY; Lee HJ; Suh JT; Lee KM
    Yonsei Med J; 2009 Dec; 50(6):764-70. PubMed ID: 20046415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of ceftolozane-tazobactam susceptibility on a French nationwide collection of Enterobacterales.
    Jousset AB; Bernabeu S; Emeraud C; Bonnin RA; Lomont A; Zahar JR; Merens A; Isnard C; Soismier N; Farfour E; Fihman V; Yin N; Barraud O; Jacquier H; Ranc AG; Laurent F; Corvec S; d'Epenoux LR; Bille E; Degand N; Plouzeau C; Guillard T; Cattoir V; Mizrahi A; Grillon A; Janvier F; Brun CL; Amara M; Bastide M; Lemonnier A; Dortet L;
    J Glob Antimicrob Resist; 2023 Mar; 32():78-84. PubMed ID: 36708769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model.
    Islam K; Sime FB; Wallis SC; Bauer MJ; Naicker S; Won H; Zowawi HM; Choudhury MA; Shirin T; Habib ZH; Harris PNA; Flora MS; Roberts JA
    Antimicrob Agents Chemother; 2022 Sep; 66(9):e0016222. PubMed ID: 35924928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The influence of hospital antimicrobial use on carbapenem-non-susceptible Enterobacterales incidence rates according to their mechanism of resistance: a time-series analysis.
    Ortiz-Brizuela E; Caro-Vega Y; Bobadilla-Del-Valle M; Leal-Vega F; Criollo-Mora E; López Luis BA; Esteban-Kenel V; Torres-Veintimilla E; Galindo-Fraga A; Olivas-Martínez A; Tovar-Calderón E; Torres-González P; Sifuentes-Osornio J; Ponce-de-León A
    J Hosp Infect; 2020 Aug; 105(4):757-765. PubMed ID: 32565368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic and biochemical characterization of OXA-405, an OXA-48-type extended-spectrum β-lactamase without significant carbapenemase activity.
    Dortet L; Oueslati S; Jeannot K; Tandé D; Naas T; Nordmann P
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3823-8. PubMed ID: 25870062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transmission of NDM-5-Producing and OXA-48-Producing Escherichia coli Sequence Type 648 by International Visitors without Previous Medical Exposure.
    Harada S; Suzuki M; Sasaki T; Sakurai A; Inaba M; Takuya H; Wakuda M; Doi Y
    Microbiol Spectr; 2021 Dec; 9(3):e0182721. PubMed ID: 34937178
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteus mirabilis - analysis of a concealed source of carbapenemases and development of a diagnostic algorithm for detection.
    Hamprecht A; Sattler J; Noster J; Stelzer Y; Fuchs F; Dorth V; Gatermann SG; Göttig S
    Clin Microbiol Infect; 2023 Sep; 29(9):1198.e1-1198.e6. PubMed ID: 37271195
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and Characteristics of Carbapenemase-Producing Enterobacteriaceae in Three Tertiary-Care Korean University Hospitals between 2017 and 2018.
    Kim SH; Kim GR; Jeong J; Kim S; Shin JH
    Jpn J Infect Dis; 2020 Nov; 73(6):431-436. PubMed ID: 32475870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissemination of an international high-risk clone of Escherichia coli ST410 co-producing NDM-5 and OXA-181 carbapenemases in Seoul, Republic of Korea.
    Kim JS; Yu JK; Jeon SJ; Park SH; Han S; Park SH; Kang M; Jang JI; Park J; Shin EK; Kim J; Hong CK; Lee JH; Hwang YO; Oh YH
    Int J Antimicrob Agents; 2021 Dec; 58(6):106448. PubMed ID: 34648943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First Isolates of OXA-48-Like Carbapenemase-Producing
    Villanueva-Cotrina F; Condori DM; Gomez TO; Yactayo KM; Barron-Pastor H
    Infect Chemother; 2022 Dec; 54(4):765-773. PubMed ID: 36596684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance of CarbaNP and CIM tests in OXA-48 carbapenemase-producing Enterobacteriaceae.
    Yıldız SS; Kaşkatepe B; Avcıküçük H; Öztürk Ş
    Acta Microbiol Immunol Hung; 2017 Mar; 64(1):9-16. PubMed ID: 28357923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of Escherichia coli and associated β-lactamases genes from diabetic foot ulcers by multiplex PCR and molecular modeling and docking of SHV-1, TEM-1, and OXA-1 β-lactamases with clindamycin and piperacillin-tazobactam.
    Shahi SK; Singh VK; Kumar A
    PLoS One; 2013; 8(7):e68234. PubMed ID: 23861873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissemination of Carbapenemases (KPC, NDM, OXA-48, IMP, and VIM) Among Carbapenem-Resistant
    Han R; Shi Q; Wu S; Yin D; Peng M; Dong D; Zheng Y; Guo Y; Zhang R; Hu F;
    Front Cell Infect Microbiol; 2020; 10():314. PubMed ID: 32719751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
    Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
    Int J Antimicrob Agents; 2021 May; 57(5):106318. PubMed ID: 33716176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activity of ceftolozane/tazobactam against Gram-negative isolates among different infections in Hong Kong: SMART 2017-2019.
    Karlowsky JA; Lob SH; Khan A; Chen WT; Woo PCY; Seto WH; Ip M; Leung S; Wong QW; Chau RWY; DeRyke CA; Young K; Motyl MR; Sahm DF
    J Med Microbiol; 2022 Apr; 71(4):. PubMed ID: 35451945
    [No Abstract]   [Full Text] [Related]  

  • 37. Structure-based functional fitness analyses of carbapenemase variants identified among pathogenic carbapenem-resistant Gram-negative bacteria.
    Pal A; Bhattacharyya I; Tripathi A
    World J Microbiol Biotechnol; 2020 Jul; 36(9):129. PubMed ID: 32712930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temocillin and piperacillin/tazobactam resistance by disc diffusion as antimicrobial surrogate markers for the detection of carbapenemase-producing Enterobacteriaceae in geographical areas with a high prevalence of OXA-48 producers.
    Huang TD; Poirel L; Bogaerts P; Berhin C; Nordmann P; Glupczynski Y
    J Antimicrob Chemother; 2014 Feb; 69(2):445-50. PubMed ID: 24055766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First Report of OXA-181-Producing
    Cuicapuza D; Alvarado L; Tocasca N; Aguilar D; Gómez-de-la-Torre JC; Salvatierra G; Tsukayama P; Tamariz J
    Microbiol Spectr; 2023 Jun; 11(3):e0458422. PubMed ID: 37022279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the simplified carbapenem inactivation method as a phenotypic detection method for carbapenemase-producing Enterobacterales.
    Yamada K; Sasaki M; Murakami H; Aoki K; Morita T; Ishii Y; Tateda K
    J Microbiol Methods; 2021 Aug; 187():106273. PubMed ID: 34157341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.